Dongkook stock gains attention as Centellian24 launches new volume lifting cream

Dongkook stock is back in focus as the company promotes a new Centellian24 volume lifting cream, while the broader KOSDAQ climbs on strong buying by foreign and institutional investors.

Dongkook (ISIN KR7086450004) stock is drawing renewed investor attention as Dongkook Pharmaceutical highlights a new volume lifting cream under its Centellian24 dermacosmetic brand, launched with a pre-release promotion on September 4, 2026 according to Asiae.

New Centellian24 product targets dermacosmetic growth

According to a report by Asiae, Dongkook Pharmaceutical announced on September 4, 2026 the launch and pre-release promotion of its Centellian24 Expert Madeca Cream Core Voluming, described as a volume lifting cream in the dermacosmetic segment.

The same Asiae report notes that the product is being positioned within Dongkook's Centellian24 brand to address consumers seeking lifting and volumizing skincare solutions, a segment where Korean dermacosmetic brands have seen growing demand.

Stock trades in positive broader market environment

While detailed intraday figures for Dongkook stock were not highlighted in the available sources, the broader Korean equity environment on September 4, 2026 provides important context for investors.

The benchmark KOSPI index closed at 6,687.21 points on September 4, 2026, up 107.73 points or 1.64 percent from the previous session, according to data reported by Yonhap News Agency.

In parallel, the KOSDAQ index, where many mid-cap healthcare and consumer names trade, closed at 813.50 points on September 4, 2026, representing a gain of 23.29 points or 2.95 percent versus the previous day, as reported by Seoul Economic Daily.

This combination of a strong KOSDAQ session and Dongkook's product-focused news provides a supportive backdrop for Dongkook stock on the Korean market as of September 4, 2026.

Centellian24 as a representative product line

Within Dongkook's portfolio, the Centellian24 dermacosmetic brand is a key representative of its consumer-facing skincare products, and the new Expert Madeca Cream Core Voluming strengthens this line.

For retail investors, the focus on dermacosmetic innovation and promotional activity around the Centellian24 brand is a central part of how Dongkook seeks to support long-term growth in the consumer health and beauty segment.

Stock perspective in the Korean market

Against a backdrop of rising KOSPI and KOSDAQ indices on September 4, 2026 and product-related news from Dongkook Pharmaceutical, Dongkook stock remains tied to broader trends in Korean healthcare and consumer sectors, including investor appetite for companies with branded dermacosmetic offerings.

Dongkook stock key data

• Company: Dongkook Pharmaceutical Co., Ltd.
• ISIN: KR7086450004
• Ticker: 086450
• Trading venue: KOSDAQ
• Sector / Industry: Pharmaceuticals / Dermacosmetics
• Index membership: KOSDAQ Index